-
Mashup Score: 3Fast Five Quiz: Hepatitis D Risk Factors - 2 month(s) ago
How familiar are you with hepatitis D and its risk factors? Test your knowledge with this quick quiz.
Source: reference.medscape.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3Management of Patients With Hepatitis D: Practical Patient Cases to Inform Your Clinical Practice - 11 month(s) ago
Follow 2 interactive patient cases to learn how best to identify and manage patients with hepatitis D.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
❗ Follow 2 interactive patient cases to learn how best to identify and manage patients with hepatitis D. #HepatitisD 🌐 Developed in collaboration with @AASLDtweets. https://t.co/H13TJRimXA
-
-
Mashup Score: 1Bulevirtide Shows Promise for Hepatitis D, Despite No FDA Approval - 11 month(s) ago
Delivery, manufacturing concerns hinder green light from US Agency, but European Medicines Agency approves treatment.
Source: Pharmacy TimesCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Although news of bulevirtide rejection by the FDA is a barrier to treatment of this severe infection #hepatitisD, recent successes with other medications on the same trajectory suggest a potential positive outcome for Bblevirtide in the future. Read More: https://t.co/2d9zMq58uF
-
-
Mashup Score: 1FDA 2022 Rewind: GI drug pipeline rattles as FDA delivers 7 new drugs, 1 costly rejection - 1 year(s) ago
Gastroenterology had a big year in 2022, with potentially game-changing FDA approvals for inflammatory bowel disease and several first-in-class therapies, yet the FDA’s rejection of the first hepatitis D therapy still looms large.Over the past year, the FDA has greenlit several notable additions to the gastroenterology armamentarium, including the first treatment for eosinophilic
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#Gastroenterology had a big year in 2022, with potentially game-changing @US_FDA approvals for #inflammatoryboweldisease and several first-in-class therapies, yet the #FDA’s rejection of the first #hepatitisD therapy still looms large #GITwitter https://t.co/8ezMu1Stsc
-
-
Mashup Score: 0Hepatitis B Foundation names Baruch S. Blumberg Prize winner - 1 year(s) ago
The Hepatitis B Foundation has awarded Stephen Urban, PhD, the 2023 Baruch S. Blumberg Prize for his development of bulevirtide, the first drug approved for the treatment of hepatitis D. “The entire hepatitis B/D community owes a tremendous debt to Dr. Urban for his conception, design and creation of new therapeutics for hepatitis B and D, as well as for his pioneering work on basic science
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
. @HepBFoundation has awarded Stephen Urban, PhD, the 2023 Baruch S. Blumberg Prize for his development of #bulevirtide (@GileadSciences), the first drug approved for the treatment of #hepatitisD #MedTwitter https://t.co/2hZikvUX7r
-
-
Mashup Score: 0
The FDA issued a complete response letter to Gilead indicating it cannot approve the company’s new drug application that seeks approval of bulevirtide for chronic hepatitis D virus infection and compensated liver disease. In its letter, the FDA cited concerns over the manufacture and delivery of bulevirtide, a first-in-class investigational entry-inhibitor; however, no new studies to assess
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI: @US_FDA rejects @GileadSciences’ #bulevirtide for #hepatitisD, compensated #liverdisease #FDA #GITwitter #MedTwitter https://t.co/k71mh8AR2k
-
-
Mashup Score: 0
The FDA issued a complete response letter to Gilead indicating it cannot approve the company’s new drug application that seeks approval of bulevirtide for chronic hepatitis D virus infection and compensated liver disease. In its letter, the FDA cited concerns over the manufacture and delivery of bulevirtide, a first-in-class investigational entry-inhibitor; however, no new studies to assess
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
The @US_FDA issued a complete response letter to @GileadSciences indicating it cannot approve the company’s new drug application that seeks approval of #bulevirtide for chronic #hepatitisD virus infection and compensated #liverdisease #FDA #GITwitter https://t.co/k71mh8AR2k
-
-
Mashup Score: 0
LONDON — Bulevirtide induced a greater combined virologic and biochemical response compared with control at 48 weeks in patients with chronic hepatitis D infection, according to research. “HDV causes the most severe form of chronic viral hepatitis with two-to-three-fold increased risk for mortality compared with HBV mono-infection,” Heiner Wedemeyer, PhD, professor and clinical
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#Bulevirtide induced a greater combined virologic and biochemical response compared with control at 48 weeks in patients with chronic #hepatitisD infection @EASLnews #ILC2022 #GITwitter #MedTwitter https://t.co/SdIdX2kUk6
-
-
Mashup Score: 1Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis - 2 year(s) ago
Background Hepatitis D virus (HDV) coinfection aggravates the course of hepatitis B virus (HBV). The prevalence of HDV in Austria is unknown. Objective This national study aimed at (i) recording t…
Source: Wiley Online LibraryCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
#HepatitisD virus prevalence in Austria is low but causes considerable morbidity due to fast progression to #cirrhosis. Read the study by @mathiasjachs & team in @UEGJournal: https://t.co/DBS4jURr7r @my_ueg @joostphdrenth @ReibergerThomas @MarkusPeck1 #OpenAccess #LiverTwitter https://t.co/rmLirtq5xB
-
-
Mashup Score: 0VIDEO: Bulevirtide improves quality of life in chronic HDV - 2 year(s) ago
Bulevirtide improved quality of life measures among patients treated for chronic hepatitis D virus, Maria Buti, MD, PhD, of the Hospital Universiario Valle Hebron, told Healio Gastroenterology. In a multicenter, randomized, phase 3 study, researchers evaluated the health-related quality of life benefits as measured by the Hepatitis Quality of Life Questionnaire (HQLQ) following 24 weeks of
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#Bulevirtide improved quality of life measures among patients treated for chronic #hepatitisD virus #NASPGHAN21 @NASPGHAN https://t.co/jugvKFOqWp
-
How familiar are you with #hepatitisD and its risk factors? https://t.co/6EiB65fDaB